Live Quote · NASDAQMNPRHealthcare· Biotechnology

Monopar Therapeutics Inc.

$97.79 2.90%(+$2.76)
TickerSpark Score
52/100
Mixed
60
Valuation
20
Profitability
15
Growth
84
Health
80
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNPR research report →

52-Week Range90% of range
Low
$29.18
Current
$97.79
High
$105.00
Company Overviewwww.monopartx.com

About the company

Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.

CEO
Chandler D. Robinson
IPO
2019
Employees
22
HQ
Wilmette, IL, US

Price Chart

+178.13% · this period
$102.05$66.23$30.42Jul 02Dec 31Jul 02
Valuation
Market Cap
$655.10M
P/E
-47.24
P/S
0.00
P/B
6.16
EV/EBITDA
-38.53
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-12.84%
ROIC
-13.80%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-13,716,894 · 11.99%
EPS
$-1.85 · -36.03%
Op Income
$-16,704,415
FCF YoY
-90.52%
Performance & Tape
52W High
$105.00
52W Low
$29.18
50D MA
$64.96
200D MA
$68.57
Beta
1.48
Avg Volume
172.31K

Get TickerSpark's AI analysis on MNPR

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 30, 26Vu Quan Anhother1,228
Jun 30, 26Vu Quan Anhother1,228
Jun 30, 26Vu Quan Anhother507
Jun 30, 26Robinson Chandlerother12,873
Jun 30, 26Robinson Chandlerother4,084
Jun 30, 26Robinson Chandlerother12,873
Jun 30, 26Cittadine Andrewother5,254
Jun 30, 26Cittadine Andrewother2,309
Jun 30, 26Cittadine Andrewother5,254
Jun 26, 26Sweeny Nicoleother1,284
Coverage · MNPR

Our MNPR coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on MNPR yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate MNPR report →
Internal Compare

Similar companies

Peers in the same neighborhood.